Literature DB >> 33517888

Enhancing disease awareness for tuberous sclerosis complex in patients with radiologic diagnosis of renal angiomyolipoma: an observational study.

Kathrin Bausch1,2, Christian Wetterauer3,4, Julian Diethelm4, Jan Ebbing3,4, Daniel T Boll4,5, Patricia Dill4,6, Cyrill A Rentsch3,4, Hans-H Seifert3,4.   

Abstract

BACKGROUND: Tuberous Sclerosis Complex (TSC) is a genetic disorder, with renal manifestations like angiomyolipoma (AML) occurring in 70-80% of patients. AML usually cause more complications in TCS patients than in non-TSC patients. However, AML patients are not routinely investigated for TSC. Our aim was to retrospectively assess the correlation between radiologically diagnosed AML and TSC.
METHODS: All patients were stratified into AML related vs. unrelated to TSC. Correlations were calculated to determine the association between age, AML, and TSC.
RESULTS: Complete data were available for 521 patients with renal AML, in 7 of which the concurrent diagnosis of TSC was found. Younger age significantly positively correlated with the prevalence of TSC in AML patients (p <  0.01). 37 (7%) of the 521 patients were within the age-range of 18-40 years, in which TSC occurred in 6 cases, 4 (66.7%) of which presented with multiple, bilateral renal AML (p <  0.05), and 2 (33.3%) of which with a single, unilateral AML (p <  0.05). In patients with AML but without TSC, unilateral AML was found in 83.9% and bilateral AML in 16.1% (p <  0.05). Simple binary logistic regression analysis revealed bilateral AML (OR 33.0; 95% CI 3.2-344.0; p = 0.003) (but not unilateral AML (OR 0.09; 95% CI 0.01-0.88; p = 0.04)) to be a risk factor for TSC.
CONCLUSIONS: The presence of bilateral AML in patients within the age-range of 18-40 years should raise suspicion for TSC as the underlying cause. Therefore, our advice is to refer patients with multiple bilateral renal AML for further investigations regarding TSC.

Entities:  

Keywords:  Angiomyolipoma; Chronic kidney disease; Renal angiomyolipoma; Tuberous sclerosis; Tuberous sclerosis complex

Mesh:

Year:  2021        PMID: 33517888      PMCID: PMC7849137          DOI: 10.1186/s12882-021-02253-w

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


  20 in total

1. 

Authors: 
Journal:  Urologe A       Date:  2019-09       Impact factor: 0.639

Review 2.  Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.

Authors:  Klemens Budde; Jens Gaedeke
Journal:  Am J Kidney Dis       Date:  2011-11-29       Impact factor: 8.860

Review 3.  Tuberous sclerosis complex: neurological, renal and pulmonary manifestations.

Authors:  D N Franz; J J Bissler; F X McCormack
Journal:  Neuropediatrics       Date:  2011-01-05       Impact factor: 1.947

4.  Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors.

Authors:  S K Rakowski; E B Winterkorn; E Paul; D J R Steele; E F Halpern; E A Thiele
Journal:  Kidney Int       Date:  2006-09-27       Impact factor: 10.612

5.  Renal lesions in tuberous sclerosis.

Authors:  T J Stillwell; M R Gomez; P P Kelalis
Journal:  J Urol       Date:  1987-09       Impact factor: 7.450

Review 6.  Renal angiomyolipomata.

Authors:  John J Bissler; J Chris Kingswood
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

Review 7.  Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria.

Authors:  E S Roach; M R Gomez; H Northrup
Journal:  J Child Neurol       Date:  1998-12       Impact factor: 1.987

Review 8.  Contemporary diagnosis and management of renal angiomyolipoma.

Authors:  Caleb P Nelson; Martin G Sanda
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

9.  Renal angiomyolipoma associated with neurofibromatosis and primary carcinoid of mesentery.

Authors:  N N Stone; I Atlas; U S Kim; D Kwan; I Leventhal; J S Waxman
Journal:  Urology       Date:  1993-01       Impact factor: 2.649

Review 10.  A quick guide to evidence-based chronic kidney disease care for the primary care physician.

Authors:  Chester H Fox; Vasu Voleti; Linda S Khan; Brian Murray; Joseph Vassalotti
Journal:  Postgrad Med       Date:  2008-07-31       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.